Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.

Gao, Y. et al.
Cancer Discovery (2019)

We report the emergence of the novel gatekeeper mutation in a patient with colon cancer treated with the allosteric MEK inhibitor binimetinib and the anti-EGFR antibody panitumumab. The mutation concurrently occurs in the same cell with and leads to RAF-independent activity but remains regulated by RAF. The V211D mutation causes resistance to binimetinib by both increasing the catalytic activity of MEK1 and reducing its affinity for the drug. Moreover, the mutant exhibits reduced sensitivity to all the allosteric MEK inhibitors tested. Thus, this mutation serves as a general resistance mutation for current MEK inhibitors; however, it is sensitive to a newly reported ATP-competitive MEK inhibitor, which therefore could be used to overcome drug resistance. SIGNIFICANCE: We report a resistance mechanism to allosteric MEK inhibitors in the clinic. A mutation developed in a patient with colon cancer on MEK and EGFR inhibitors. This mutant increases the catalytic activity of MEK1 and reduces its affinity for binimetinib, but remains sensitive to ATP-competitive MEK inhibitors..


Gao, Y., Maria, A., Na, N., da Cruz Paula, A., Gorelick, A.N., Hechtman, J.F., Carson, J., Lefkowitz, R.A., Weigelt, B., Taylor, B.S., Zhao, H., Reis-Filho, J.S., de Stanchina, E., Rosen, N., Yao, Z., Yaeger, R.


Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing
Lim, K.
Blood Advances
Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia
Demaree, B.
Nature Communications
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
Peretz, C.A.C
Blood Advances (2021)
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Alyssa L. Kennedy
Nature Communications (2021)